A Multimodality Approach to Addressing New Drug Approvals
Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS® and Erica Fischer-Cartlidge, DNP, RN, AOCNS®, EBP(CH)

Overview of Drug Development
The pace of innovation in oncology treatment is rapidly increasing with rising numbers of novel active substances and faster speed to launch.

- In 2023, the FDA approval 55 novel drugs, the second highest count in 30 years.
- 51% of novel drug approvals received orphan drug designation.
- 65% of novel drug approvals used one or more of the expedited programs, including Fast Track, Breakthrough Therapy, Priority Review, or Accelerated Approval.
- 36% of novel drug approvals were identified as first-in-class.

In response to the rapid drug development process and its impact on oncology care, ONS sought to enhance existing opportunities to communicate drug information to nurses to meet these need using a multimodality approach.

Oncology Drug Reference Sheet
Newly formatted drug reference sheets are published monthly and as needed in ONS Voice. The table layout improves readability and ease of use at the point of care.

Huddle Cards
One-page reference sheets to provide bite-sized learning on drug classes and drug development terminology.

Oral and IV Drug Education Sheets
Collaboratively developed patient education sheets designed for clinician-led discussions.

Oncology Nursing Podcast
Pharmacology 101 podcast series talks through mechanism of action and standard side effect management.
- Alkylating Agents
- Antimetabolites
- Plant Alkaloids

Project Livin’ Label
Collaborative webinar discussions on drug development and labeling details with perspectives of physicians, pharmacists, nurses, patients, and industry.

Summary
The acceleration of new drug development and approval requires that professional associations and healthcare organizations create agile, multimodal forms of drug education to keep pace with the pharmaceutical industry and meet the unique needs and adult learning styles of the audiences they serve. Equipping clinicians with up-to-date, evidence-based information on novel drugs promotes safe care delivery and accurate, comprehensive patient education.

Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS® and Erica Fischer-Cartlidge, DNP, RN, AOCNS®, EBP(CH)